Survival
At the time of analysis (March 22, 2022), the median (IQR) follow-up time for the surviving patients in the ITT population was 42.9 (38.8-47.0) months in the CRTCT group and 44.4 (39.3-49.4) months in the RT group. The median (IQR) OS was 28.1 (19.7-36.6) months in the CRTCT group and 20.1 (13.8-26.5) months in the RT group. The OS rates in the CRTCT group and RT group were 72.2% vs 62.3% at 1 year, 55.7% vs 43.8% at 2 years, and 46.2% vs 33.9% at 3 years (hazard ratio [HR], 0.73; 95% CI, 0.56-0.96; log-rank 